Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REDEFINE 5 (vs semaglutide 2.4 mg)

REDEFINE 5 (vs semaglutide 2.4 mg)

CagriSema · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
obesity
Official title
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2023-04 → 2025-01
Participants
331
Duration
68 weeks
Registry
NCT05813925

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg: −11.9 % (efficacy)obesity68164−18.4 %−16.9 %−1.12.010.0——4.0−10.0verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (7)
  • CagriSema 2.4/2.4 mg · weight_eff · Table 2
    Change in bodyweight† −18·4% −11·9% −6·5 (−8·4 to −4·6) <0·0001
  • CagriSema 2.4/2.4 mg · weight_tp · Results, paragraph 4 (treatment policy estimand)
    had a mean change in bodyweight of –16·9% (0·7) versus –11·1% (0·7) for semaglutide
  • CagriSema 2.4/2.4 mg · ae_dc · Results, paragraph 10; Table 3
    cagrilintide–semaglutide group (three [2%] participants) and the semaglutide group (four [2%]; table 3)
  • CagriSema 2.4/2.4 mg · disc_any · Summary, Findings; Results paragraph 1
    17 (10%) participants discontinued cagrilintide–semaglutide and ten (6%) discontinued semaglutide.
  • CagriSema 2.4/2.4 mg · sae · Results, paragraph 10; Table 3
    Serious adverse events were reported in six (4%) participants receiving cagrilintide–semaglutide and 11 (7%) receiving semaglutide
  • CagriSema 2.4/2.4 mg · hba1c · Table 2
    Change in HbA1c, %§ −1·1 −1·0 −0·1 (−0·2 to 0·0) 0·017
  • CagriSema 2.4/2.4 mg · sbp · Table 2
    Change in systolic blood pressure, mmHg§ −10·0 −5·2 −4·9 (−7·7 to −2·0) 0·0008

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REDEFINE 5 (vs semaglutide 2.4 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.